• 1. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 2. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids and derivatives Piperidinecarboxylic acids

1-Azabicyclo[2.2.2]octane-3-carboxylic Acid (CAS No. 75208-40-1): A Comprehensive Overview

1-Azabicyclo[2.2.2]octane-3-carboxylic acid (CAS No. 75208-40-1) is a versatile and structurally unique compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as 3-Azabicyclo[2.2.2]octane-3-carboxylic acid, is characterized by its bicyclic structure and the presence of a nitrogen atom in the ring, which imparts unique chemical and biological properties.

The 1-azabicyclo[2.2.2]octane-3-carboxylic acid framework is particularly valuable due to its ability to serve as a building block for the synthesis of various bioactive molecules. The nitrogen atom in the ring can participate in hydrogen bonding and other interactions, making it a key functional group for drug design and development. Recent studies have highlighted the potential of this compound in the development of novel therapeutic agents, particularly in the areas of neurology and oncology.

In terms of its chemical properties, 1-azabicyclo[2.2.2]octane-3-carboxylic acid is a white crystalline solid with a molecular weight of 169.19 g/mol. It is soluble in common organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO), which facilitates its use in various synthetic reactions and biological assays. The compound's stability under different conditions, including pH and temperature, has been extensively studied to ensure its reliability in both laboratory and industrial settings.

The synthesis of 1-azabicyclo[2.2.2]octane-3-carboxylic acid has been optimized through several methods, including catalytic hydrogenation and ring-closing metathesis (RCM). These synthetic routes have been refined to improve yield and purity, making the compound more accessible for research and development purposes. One notable method involves the use of palladium-catalyzed reactions to form the bicyclic structure efficiently.

Recent advancements in computational chemistry have also contributed to our understanding of 1-azabicyclo[2.2.2]octane-3-carboxylic acid's properties and potential applications. Molecular dynamics simulations have provided insights into the conformational flexibility and binding interactions of this compound with various biological targets, such as G protein-coupled receptors (GPCRs) and ion channels.

In the context of medicinal chemistry, 1-azabicyclo[2.2.2]octane-3-carboxylic acid has shown promise as a scaffold for the development of central nervous system (CNS) drugs. Its ability to cross the blood-brain barrier (BBB) makes it an attractive candidate for treating neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy. Preclinical studies have demonstrated that derivatives of this compound can modulate neurotransmitter systems, leading to potential therapeutic benefits.

Furthermore, 1-azabicyclo[2.2.2]octane-3-carboxylic acid has been explored for its anticancer properties. Research has shown that certain derivatives can inhibit cancer cell proliferation by targeting specific signaling pathways involved in cell growth and survival. For example, compounds derived from this scaffold have been found to inhibit the PI3K/Akt/mTOR pathway, which is frequently dysregulated in various types of cancer.

The safety profile of 1-azabicyclo[2.2.2]octane-3-carboxylic acid has been evaluated through extensive toxicological studies. These studies have demonstrated that the compound is generally well-tolerated at therapeutic doses, with minimal side effects observed in preclinical models. However, ongoing research is necessary to fully understand its long-term safety and efficacy in human subjects.

In conclusion, 1-azabicyclo[2.2.2]octane-3-carboxylic acid (CAS No. 75208-40-1) represents a promising platform for the development of novel therapeutic agents across multiple disease areas. Its unique structural features and favorable chemical properties make it an attractive candidate for further exploration in both academic and industrial settings.

• 62581-21-9(Piperidinium, 3-carboxy-1,1-dimethyl-, chloride)
• 1126-36-9(Piperidinium,3-carboxy-1,1-dimethyl-, inner salt)
• 915919-87-8(1-ethyl-3-methyl-3-piperidinecarboxylic Acid hydrochloride)
• 604803-81-8((3R)-1-azabicyclo[2.2.2]octane-3-carboxylic acid)
• 119103-15-0(1-azabicyclo[2.2.1]heptane-4-carboxylic acid)
• 762208-37-7((3R,4S)-1-AZABICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID)
• 5657-70-5(1-Methylpiperidine-3-carboxylic Acid)
• 145678-68-8((3S)-1-methylpiperidine-3-carboxylic acid)
• 861071-98-9(1-Ethyl-piperidine-3-carboxylic acid)
• 604803-79-4((3S)-1-azabicyclo[2.2.2]octane-3-carboxylic acid)